Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy.

IF 2.2 Q3 ONCOLOGY
Karunya A S, Sudeep Kumara K, Avin Kumar, Kamalaksh Shenoy
{"title":"Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy.","authors":"Karunya A S, Sudeep Kumara K, Avin Kumar, Kamalaksh Shenoy","doi":"10.1186/s43046-026-00398-z","DOIUrl":null,"url":null,"abstract":"<p><p>Head and neck cancer (HNC), a heterogeneous group of malignancies that arising from the mucosal surfaces of the Upper Aerodigestive Tract (UADT), is a major health concern worldwide. By 2050, the number of cancer cases worldwide is expected to reach 35 million, with nearly half of all new cases and deaths occurring in Asia. In India, HNC is particularly prevalent accounting for about 30% of the global burden, with lip and oral cavity cancers (OCC) make up 10.17% of all cases, highlighting a serious public health crisis. A comparative analysis of GLOBOCAN 2022 data reveals a significant variation in HNC burden; India's overall Age-Standardized Incidence Rate (ASIR) for lip and OCC is 9.8, which is considerably higher than the Asian average of 3.2 and the global average of 4.1. Indian males facing a particularly high burden (ASIR: 14.7) compared to females (ASIR: 4.9). While India leads in sites such as the larynx and hypopharynx, it maintains a notably lower burden of nasopharyngeal cancer (ASIR: 0.4) compared to the rest of Asia (ASIR: 1.9). High Mortality-to-Incidence Ratio (MIR) persist across all sub-sites, with tobacco, alcohol, and Human Papillomavirus (HPV) being the main risk factors. This review critically analyses HNC literature by integrating historical perspectives with recent progress in radiation therapy (RT). This includes Three- Dimensional Conformal Radiation Therapy (3DCRT), Intensity- Modulated Radiation Therapy (IMRT), Image Guided Radiation Therapy (IGRT), Volumetric Modulated Arc Therapy (VMAT), and new methods like Stereotactic Radiosurgery (SRS), Stereotactic Radiotherapy (SRT), Stereotactic Body Radiation Therapy (SBRT), Tomotherapy, Proton therapy (PT) and Adaptive Radiotherapy (ART). Radiotherapy remains a cornerstone of treatment, with its success relying on precise technology and accurate treatment delivery. By analysing epidemiology, risk factors, and evolving clinical approaches, this work creates a clear framework for current management and highlights future directions to improve patient quality of life and treatment results.</p>","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"38 1","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2026-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13499771/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Egyptian National Cancer Institute","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s43046-026-00398-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Head and neck cancer (HNC), a heterogeneous group of malignancies that arising from the mucosal surfaces of the Upper Aerodigestive Tract (UADT), is a major health concern worldwide. By 2050, the number of cancer cases worldwide is expected to reach 35 million, with nearly half of all new cases and deaths occurring in Asia. In India, HNC is particularly prevalent accounting for about 30% of the global burden, with lip and oral cavity cancers (OCC) make up 10.17% of all cases, highlighting a serious public health crisis. A comparative analysis of GLOBOCAN 2022 data reveals a significant variation in HNC burden; India's overall Age-Standardized Incidence Rate (ASIR) for lip and OCC is 9.8, which is considerably higher than the Asian average of 3.2 and the global average of 4.1. Indian males facing a particularly high burden (ASIR: 14.7) compared to females (ASIR: 4.9). While India leads in sites such as the larynx and hypopharynx, it maintains a notably lower burden of nasopharyngeal cancer (ASIR: 0.4) compared to the rest of Asia (ASIR: 1.9). High Mortality-to-Incidence Ratio (MIR) persist across all sub-sites, with tobacco, alcohol, and Human Papillomavirus (HPV) being the main risk factors. This review critically analyses HNC literature by integrating historical perspectives with recent progress in radiation therapy (RT). This includes Three- Dimensional Conformal Radiation Therapy (3DCRT), Intensity- Modulated Radiation Therapy (IMRT), Image Guided Radiation Therapy (IGRT), Volumetric Modulated Arc Therapy (VMAT), and new methods like Stereotactic Radiosurgery (SRS), Stereotactic Radiotherapy (SRT), Stereotactic Body Radiation Therapy (SBRT), Tomotherapy, Proton therapy (PT) and Adaptive Radiotherapy (ART). Radiotherapy remains a cornerstone of treatment, with its success relying on precise technology and accurate treatment delivery. By analysing epidemiology, risk factors, and evolving clinical approaches, this work creates a clear framework for current management and highlights future directions to improve patient quality of life and treatment results.

头颈癌:流行病学、全球负担和放疗进展的综合综述。
头颈癌(HNC)是一种起源于上呼吸道(UADT)粘膜表面的异质性恶性肿瘤,是全世界关注的主要健康问题。到2050年,全球癌症病例数预计将达到3500万,其中近一半的新病例和死亡病例发生在亚洲。在印度,HNC尤为普遍,约占全球负担的30%,唇癌和口腔癌(OCC)占所有病例的10.17%,突显出严重的公共卫生危机。GLOBOCAN 2022数据的对比分析显示,HNC负担存在显著差异;印度唇部和OCC的总体年龄标准化发病率(ASIR)为9.8,远高于亚洲平均水平3.2和全球平均水平4.1。与女性(ASIR: 4.9)相比,印度男性面临着特别高的负担(ASIR: 14.7)。虽然印度在喉部和下咽等部位处于领先地位,但与亚洲其他地区(ASIR: 1.9)相比,它的鼻咽癌负担明显较低(ASIR: 0.4)。高死亡率与发病率比(MIR)持续存在于所有亚位点,烟草、酒精和人乳头瘤病毒(HPV)是主要的危险因素。这篇综述通过结合放射治疗(RT)的历史观点和最新进展,批判性地分析了HNC文献。这包括三维适形放射治疗(3DCRT),调强放射治疗(IMRT),图像引导放射治疗(IGRT),体积调制电弧治疗(VMAT),以及立体定向放射外科(SRS),立体定向放射治疗(SRT),立体定向体放射治疗(SBRT),断层治疗,质子治疗(PT)和适应性放射治疗(ART)等新方法。放射治疗仍然是治疗的基石,其成功依赖于精确的技术和准确的治疗。通过分析流行病学、风险因素和不断发展的临床方法,这项工作为当前的管理创造了一个清晰的框架,并强调了改善患者生活质量和治疗结果的未来方向。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.50
自引率
0.00%
发文量
46
审稿时长
11 weeks
期刊介绍: As the official publication of the National Cancer Institute, Cairo University, the Journal of the Egyptian National Cancer Institute (JENCI) is an open access peer-reviewed journal that publishes on the latest innovations in oncology and thereby, providing academics and clinicians a leading research platform. JENCI welcomes submissions pertaining to all fields of basic, applied and clinical cancer research. Main topics of interest include: local and systemic anticancer therapy (with specific interest on applied cancer research from developing countries); experimental oncology; early cancer detection; randomized trials (including negatives ones); and key emerging fields of personalized medicine, such as molecular pathology, bioinformatics, and biotechnologies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书